A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases.
Carcinoma, Hepatocellular
/ drug therapy
Drugs, Investigational
/ therapeutic use
Fluorodeoxyglucose F18
/ therapeutic use
Humans
Liver Neoplasms
/ pathology
Lung Neoplasms
/ secondary
Male
Middle Aged
Muscle, Skeletal
/ diagnostic imaging
Skull
/ pathology
Sorafenib
/ therapeutic use
Tegafur
/ therapeutic use
Hepatocellular carcinoma
Semimembranosus and semitendinosus muscles metastasis
Skull metastasis
Sorafenib
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
12
02
2022
accepted:
24
06
2022
pubmed:
15
7
2022
medline:
28
9
2022
entrez:
14
7
2022
Statut:
ppublish
Résumé
We report a case in which multidisciplinary treatment was effective for hepatocellular carcinoma (HCC) with cranial and skeletal muscle metastases. A 55-year-old male with HCC received sorafenib for lung metastases. He was admitted to our hospital due to the skull metastasis detected by fluorodeoxyglucose positron emission tomography (FDG-PET). The patient underwent resection for skull metastasis. After the surgical treatment, he was treated with sorafenib again. Eight months after craniectomy, FDG-PET showed FDG uptake in the semimembranosus and semitendinosus muscles. Histopathological examination of the muscle biopsy revealed HCC muscle metastasis. Sorafenib treatment was discontinued. The investigational new drug (tegafur-gimeracil-oteracil) and tegafur-uracil were used for the treatment. These treatments proved to be ineffective as the lung metastases enlarged and new metastases appeared on the mediastinal lymph nodes and dura cava. The patient was unable to walk due to the enlarged thigh muscle metastases. Sorafenib was re-administered, which reduced the enlargement of the lung and mediastinal lymph nodes. Dural metastases were treated with resection and radiotherapy. Additional radiation therapy to the thigh muscles relieved the patient from pain experienced during walking. Sorafenib treatment was continued for the next 3 years. The patient survived for 4 years after the skull resection.
Identifiants
pubmed: 35834168
doi: 10.1007/s12328-022-01669-7
pii: 10.1007/s12328-022-01669-7
doi:
Substances chimiques
Drugs, Investigational
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Tegafur
1548R74NSZ
Sorafenib
9ZOQ3TZI87
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
960-967Subventions
Organisme : JSPS KAKENHI Grant
ID : 20K08312
Informations de copyright
© 2022. Japanese Society of Gastroenterology.
Références
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62.
pubmed: 30970190
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
pubmed: 33479224
Bhatia R, Ravulapati S, Befeler A, et al. Hepatocellular carcinoma with bone metastases: incidence, prognostic significance, and management-single-center experience. J Gastrointest Cancer. 2017;48:321–5.
pubmed: 28891006
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.
pubmed: 16298014
Hiraoka A, Michitaka K, Kumada T, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6:325–36.
pubmed: 29234636
pmcid: 5704689
Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2001;13:1083–8.
pubmed: 11564960
McIver JI, Scheithauer BW, Rydberg CH, et al. Metastatic hepatocellular carcinoma presenting as epidural hematoma: case report. Neurosurgery. 2001;49:447–9.
pubmed: 11504122
Goto T, Dohmen T, Miura K, et al. Skull metastasis from hepatocellular carcinoma with chronic hepatitis B. World J Gastrointest Oncol. 2010;2:165–8.
pubmed: 21160825
pmcid: 2999177
Hsieh CT, Sun JM, Tsai WC, et al. Skull metastasis from hepatocellular carcinoma. Acta Neurochir (Wien). 2007;149:185–90.
Kim YS, Moon KS, Lee KH, et al. Spontaneous acute epidural hematoma developed due to skull metastasis of hepatocelluar carcinoma: a case report and review of the literature. Oncol Lett. 2016;11:741–4.
pubmed: 26870277
Chye CL, Lin KH, Ou CH, et al. Acute spontaneous subdural hematoma caused by skull metastasis of hepatocellular carcinoma: case report. BMC Surg. 2015;15:60.
pubmed: 25958386
pmcid: 4432998
Sadik KW, Dayoub H, Bonatti H. Superior sagittal sinus tumor eroding through the skull: an unfamiliar presentation of hepatocellular carcinoma and literature review. Case Rep Surg. 2019;2019:5945726.
pubmed: 31781465
pmcid: 6875341
Chamoun RB, DeMonte F. Management of skull base metastases. Neurosurg Clin N Am. 2011;22(61–6):vi–ii.
Stark AM, Eichmann T, Mehdorn HM. Skull metastases: clinical features, differential diagnosis, and review of the literature. Surg Neurol. 2003;60:219–25 (discussion 25-6).
pubmed: 12922038
Soffietti R, Cornu P, Delattre JY, et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol. 2006;13:674–81.
pubmed: 16834697
Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–9.
pubmed: 9809728
Wu MH, Wu YM, Lee PH. The psoas muscle as an unusual site for metastasis of hepatocellular carcinoma: report of a case. Surg Today. 2006;36:280–2.
pubmed: 16493542
Yau T, Wong H, Chan P, et al. Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease course. World J Surg Oncol. 2008;6:42.
pubmed: 18430252
pmcid: 2373298
Sano T, Izuishi K, Takebayashi R, et al. Education and imaging hepatobiliary and pancreatic: isolated diaphragmatic metastasis from hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1475.
pubmed: 19702916
Sirigu D, Loi L, Mura R, et al. Muscle metastasis from hepatocellular carcinoma in a patient treated with TACE. J Ultrasound. 2009;12:45–7.
pubmed: 23396657
pmcid: 3552931
Michalaki V, Zygogianni A, Kouloulias V, et al. Muscle metastasis from hepatocellular carcinoma. J Cancer Res Ther. 2011;7:81–3.
pubmed: 21546750
Furumoto K, Miura K, Nagashima D, et al. Solitary metastasis to the intercostal muscle from hepatocellular carcinoma: a case report. Int J Surg Case Rep. 2012;3:322–6.
pubmed: 22554941
pmcid: 3356537
Jiang H, Wang Z, Xian J, et al. Bilateral multiple extraocular muscle metastasis from hepatocellular carcinoma. Acta Radiol Short Rep. 2012;1:1–3.
Jo S, Shim HK. A patient who has survived for a long period with repeated radiotherapies for multifocal extrahepatic metastases from hepatocellular carcinoma. Radiat Oncol J. 2013;31:267–72.
pubmed: 24501717
pmcid: 3912243
Subramaniam N, Hiremath B, Pujar A. Metastasis of diffuse hepatocellular carcinoma to an extremely unusual site. BMJ Case Rep. 2013;2013:bcr2013200437.
pubmed: 24057331
pmcid: 3794214
Traficante D, Assalone P, Tomei F, et al. A case report of HCC cutaneous metastasis. J Gastrointest Oncol. 2014;5:E65–7.
pubmed: 25083308
pmcid: 4110500
Rahim EA, Noh MS, Ngah NA, et al. Hepatocellular carcinoma with disseminated skeletal muscle metastasis. Acta Radiol Open. 2017;6:2058460117716705.
pubmed: 28811928
pmcid: 5528193
Takahashi K, Putchakayala KG, Safwan M, et al. Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: a case report. World J Hepatol. 2017;9:973–8.
pubmed: 28839518
pmcid: 5550763
Orita K, Sakamoto A, Okamoto T, et al. Solitary muscle metastasis of hepatocellular carcinoma to the biceps femoris muscle with only elevated serum PIVKA-II: a case report. Am J Case Rep. 2019;20:306–9.
pubmed: 30846677
pmcid: 6419530
Nakayama A, Arai J, Otoyama Y, et al. Muscular metastasis of hepatocellular carcinoma: case report and literature review. Intern Med (Tokyo, Japan). 2021. https://doi.org/10.2169/internalmedicine.7200-21 .
doi: 10.2169/internalmedicine.7200-21
Song Q, Sun XF, Wu XL, et al. Skeletal muscle metastases of hepatocellular carcinoma: a case report and literature review. World J Clin Cases. 2021;9:3334–41.
pubmed: 34002142
pmcid: 8107905
Cha J, Seong J, Lee IJ, et al. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J. 2013;54:1178–85.
pubmed: 23918567
pmcid: 3743177
Guo X, Xu Y, Wang X, et al. Advanced hepatocellular carcinoma with bone metastases: prevalence, associated factors, and survival estimation. Med Sci Monit. 2019;25:1105–12.
pubmed: 30739123
pmcid: 6378855
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650–9.
pubmed: 32215577
pmcid: 7225913
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England). 2019;393:2051–8.
Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82.
pubmed: 27789196
pmcid: 5143183
Kim TH, Park S, Rim CH, et al. Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma. J Cancer Res Clin Oncol. 2021;147:2693–700.
pubmed: 33582874
Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181–223.
pubmed: 34239808
pmcid: 8237791
Jin K, Lan H, Wang X, et al. Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing. Int J Clin Exp Pathol. 2017;10:10495–504.
pubmed: 31966388
pmcid: 6965764
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.
pubmed: 32402160
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England). 2018;391:1163–73.
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;389:56–66.
Zhu AX, Finn RS, Galle PR, et al. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein. Lancet Oncol. 2019;20: e191.
pubmed: 30942178
Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63.
pubmed: 29972759
pmcid: 7523244